

SPECIAL SYMPOSIUM ON STRATEGY FOR
PLASMODIUM FALCIPARUM
BLOOD-STAGE VACCINE DEVELOPMENT
AND CLINICAL TRIALS

Introduction— Carter L. Diggs	1
The promise of asexual malaria vaccine development— Brittan L. Pasloske and Russell J. Howard	3
Expression systems that best mimic native structure: which ones to try first and why— Sandra P. Chang ..	11
Protein expression in yeast as an approach to production of recombinant malaria antigens— Ian C. Bathurst	20
Immunity to erythrocytic stages of malarial parasites— Carole A. Long, Thomas M. Daly, Peter Kima, and Indresh Srivastava	27
The potential for recruiting immune responses toward type 1 or type 2 T cell help— Basil Golding, Marina Zaitseva, and Hana Golding	33
Liposomes, muramyl dipeptide derivatives, and nontoxic lipid A derivatives as adjuvants for human malaria vaccines— George S. N. Hui	41
Copolymer adjuvants in malaria vaccine development— Robert L. Hunter and Altaf A. Lal	52
Clinical trials of <i>Plasmodium falciparum</i> erythrocytic stage vaccines— W. Ripley Ballou	59
Panel Discussion	66